NOTE: This video is ONLY available to watch in selected countries and geographies [geoip-content country=”AT, BE, BG, HR, CY, CZ, DK, EE, FI, FR, DE, GR, HU, IE, IT, LV, LT, LU, MT, NL, PL, PT, RO, SK, SI, CH, ES, SE, GB, AL, AD, AM, AZ, BY, BA, GE, IS, KZ, LI, MD, MC, ME, MK, NO, RU, SM, RS, CH, TR, UA, VA, AF, AU, BD, BT, BN, KH, CN, FJ, HK, IN, JP, KI, LA, MO, MV, MN, MM, NP, NZ, PK, PG, PH, AS, SG, KR, LK, TW, TH, TO, TV, VU, VN, BH, CY, EG, IR, IQ, IL, JO, KW, LB, OM, PS, QA, SA, SY, TR, AE, YE”]
Ralf Langhoff (Berlin, Germany) talks to Vascular News about the 12-month data from the CONSEQUENT study, which aims to assess the safety and efficacy of the SeQuent® Please OTW (B. Braun) drug-coated balloon (DCB) in peripheral arterial disease (PAD) patients with above- and below the-knee lesions.
The study, notes Langhoff, indicates that the overall mortality rate of the device is “very low”. Indeed, the mortality rate for the non-CLI group was 2% compared to 7% in the CLI group. It was also found that there was “no correlation” between the paclitaxel dose and mortality rate. Langhoff noted the patency rate of 89.9% and target lesion revascularisation (TLR) rate of 6.3% in the CLI group, compared to 87.1% and 9.6% in the non-CLI group. He states that this is “robust and convincing data” especially considering the “challenging” lesion lengths.
Langhoff goes on to give his views on the DCB-only strategy before outlining in which patients a spot and focal stenting strategy with the VascuFlex® LOC system is appropriate.
This video is sponsored by B. Braun.
[/geoip-content]
